Publication of the technology behind Nanovi’s liquid fiducial markers reveals broad application potential in radiation therapy and surgery
16 September 2020
- A unique carbo-gel based liquid soft tissue marker system
- Bridging high-resolution imaging with therapeutic intervention for better cancer care
- Patents co-owned by Nanovi and the Technical University of Denmark (DTU)
- Nanovi holds global commercialization rights in radiation therapy and surgery
- First products, BioXmark® and PetXmark™, developed and marketed by Nanovi
Copenhagen, 16 September 2020 – Nanovi informs that the platform technology behind the company and its portfolio of liquid fiducial markers has been published in Science Advances. Science Advances is one of the world’s top-ranked scientific journals with an impact factor of +13 (2019).
Under the title “Multimodal soft tissue markers for bridging high-resolution diagnostic imaging with therapeutic invention”, the publication presents a unique, adaptable liquid soft tissue marker system based on functionalized carbohydrates (Carbo-gels). The publication also reveals broad medical application relevance for the system in radiation therapy and surgery.
The soft tissue marker technology is a co-invention between Nanovi and the Health Technology department of the Technical University of Denmark, DTU. Under a collaboration agreement with the DTU, Nanovi holds global development and commercialization rights to the technology in the fields of photon and proton-based IGRT and surgery.
“The publication of our invention is a major milestone”, said Thomas L. Andresen, professor at DTU Health Technology, co-author on the publication and member of Nanovi’s Board of Directors. “It shows encouraging proof-of-concept for the image features, the physical properties and the tolerance profile of fiducial markers from this unique liquid marker system. I am confident that multi-modal markers have broad potential to improve both IGRT and surgical inventions, including robotic procedures.”
Nanovi has developed its first two liquid fiducial markers based on the technology to enhance target visibility on imaging and enable high precision radiation therapy of cancer patients:
- BioXmark® is marketed in Europe to radiographically mark soft tissue in humans
- PetXmark™ is marketed in the US to radiographically mark subcutaneous tissue in dogs and cats
“With the market entries of BioXmark® in Europe and PetXmark™ in the US, this novel liquid marker system has already demonstrated its clinical relevance in cancer care” Jesper Boysen, CEO of Nanovi, added, “Our fiducial markers offer customizable implantation, positional stability and visibility as well as photon and proton compatibility as tools to empower healthcare professionals to continuously improve the treatment of cancer patients.”
Link to the Publication:
Hansen AE, Henriksen JR, Jølck RI, Fliedner FP, Bruun LM, Scherman J, Jensen AI, Munck af Rosenschöld Per, Moorman L, Kurbegovic S, de Blanck SR, Larsen KR, Clementsen PF, Christensen AN, Clausen MH, Wang W, Kempen P, Christensen M, Viby N-E, Persson G, Larsen R, Conradsen K, McEvoy FJ, Kjaer A, Eriksen T, Andresen TL. Multimodal soft tissue markers for bridging high-resolution diagnostic imaging with therapeutic intervention. Sci Adv [Internet]. 2020 Aug 19 [cited 2020 Sep 29];6(34).
Jesper Boysen, CEO
Phone: +45 24 65 60 33